Home > Insider Trading > Filing (0001209191-20-024148)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1503802	Karyopharm Therapeutics Inc.	KPTI	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1364719	Michael Kauffman	C/O Karyopharm Therapeutics Inc. 85 Wells Avenue Newton MA 02459	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-04-09	10,000	$4.75	565,122	No	4	M	Direct
Common Stock	Disposition	2020-04-09	10,000	$20.64	555,122	No	4	S	Direct
Common Stock	Acquisiton	2020-04-08	10,000	$4.75	766,489	No	4	M	Indirect	By Spouse
Common Stock	Disposition	2020-04-08	10,000	$18.61	756,489	No	4	S	Indirect	By Spouse

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct
No	4	M	Indirect	By Spouse
No	4	S	Indirect	By Spouse

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2020-04-09	10,000	$0.00	10,000	$4.75
Common Stock	Stock Option (right to buy)	Disposition	2020-04-08	10,000	$0.00	10,000	$4.75

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
356,061		2023-09-02	No	4	M	Direct
400,303		2023-09-02	No	4	M	Indirect

Footnotes

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.36 to $20.99, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.15 to $19.06, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter.